Provided by Tiger Trade Technology Pte. Ltd.

Rhythm Pharmaceuticals Inc.

80.95
-0.9500-1.16%
Volume:31.72K
Turnover:2.59M
Market Cap:5.53B
PE:-26.06
High:83.65
Open:81.00
Low:80.57
Close:81.90
52wk High:122.20
52wk Low:45.91
Shares:68.29M
Float Shares:55.48M
Volume Ratio:1.22
T/O Rate:0.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1057
EPS(LYR):-3.1100
ROE:-90.45%
ROA:-27.51%
PB:39.75
PE(LYR):-26.03

Loading ...

FDA approves Rhythm Pharmaceuticals' IMCIVREE for acquired hypothalamic obesity in patients aged 4 and older

Reuters
·
Mar 20

Rhythm Pharmaceuticals Announces FDA Approval of Imcivree® (Setmelanotide) for Patients With Acquired Hypothalamic Obesity

THOMSON REUTERS
·
Mar 20

NASDAQ TRADE HALT HALT NEWS PENDING AT 06:25 PM

Reuters
·
Mar 20

Rhythm price target lowered to $100 from $110 at H.C. Wainwright

TIPRANKS
·
Mar 18

Rhythm Pharmaceuticals, Inc. : H.c. Wainwright Cuts Target Price to $100 From $110

THOMSON REUTERS
·
Mar 18

These Stocks Are Today's Movers: Nvidia, Oklo, Delta, Carnival, Uber, Honeywell, Elbit, and More -- Barrons.com

Dow Jones
·
Mar 17

Rhythm Pharmaceuticals Inc : Leerink Partners Cuts Target Price to $136 From $142

THOMSON REUTERS
·
Mar 17

Rhythm Pharmaceuticals Is Maintained at Buy by Needham

Dow Jones
·
Mar 17

Guggenheim Sticks to Its Buy Rating for Rhythm Pharmaceuticals (RYTM)

TIPRANKS
·
Mar 17

Analysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (RYTM) and Merck & Company (MRK)

TIPRANKS
·
Mar 17

RBC Lowers Price Target on Rhythm Pharmaceuticals to $130 From $140, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Mar 17

Rhythm Pharmaceuticals Inc : Needham Cuts Target Price to $130 From $139

THOMSON REUTERS
·
Mar 17

Rhythm Pharmaceuticals price target lowered to $152 from $176 at Citizens

TIPRANKS
·
Mar 17

Rhythm Pharmaceuticals Inc : RBC Cuts Target Price to $130 From $140

THOMSON REUTERS
·
Mar 17

Stocks to Watch: Lensar, Rhythm Pharmaceuticals, TruBridge, Kaltura

Dow Jones
·
Mar 17

BRIEF-Rhythm Pharmaceuticals Announces Topline Results From Phase 3 Emanate Trial

Reuters
·
Mar 17

Rhythm Pharma Exec Says the 2022‑Launched Trial Was Partly Affected by the Rise of Glp‑1 Drugs, Which May Have Contributed to High Patient Dropout Rates

THOMSON REUTERS
·
Mar 17

Rhythm Pharma Exec Says Most Placebo Patients Stopped Treatment by Choice, While Most Setmelanotide Patients Discontinued Because of Side Effects

THOMSON REUTERS
·
Mar 17

Rhythm Pharma Exec Says Emanate Trail Saw an Avg 40% to 60% Patient Dropout Rate Across All Groups - Conf Call

THOMSON REUTERS
·
Mar 17

Rhythm reports EMANATE trial substudies did not meet primary endpoints

TIPRANKS
·
Mar 17